A B S T R A C T Since lithium has been showx%n to inhibit release of iodine from the thyroid, we have investigated its therapeutic potential in thvrotoxicosis. Eight detailed "lI kinetic studies were performed on seven thvrotoxic women and data was analy,zed using a computer program. Lithium at serum levels of about 1 mEq 'liter decreased the loss of '31I from the thyroid, led to a fall in serum "II levels and diminished urinary "'I excretion. Coinputer simulation of the lithium effect required, in every case, that lithium inhibit hormonal and( nonllormonal thyroid iodine release. In five cases a second lithium effect was required for a satisfactory fit of the model soluton with observed data: namely, an inhibition of hormone disappearance from serunm.
INTRODUCTION
Althouglh lithium (1 ) salts have been used to treat maniicdepressive psychoses since 1948 (2) , it was only in 1967 that goiter was noted in some of these patients (3) . In- vestigation of the mechanism of goitrogenesis suggested that lithiumii ion blocks the release of iodine from thvroid gland -without significantly impairing other aspects of thyroid function. This Xwas first proposed by Sedvall (4) Who observed a prolonged thlroid "'I half-life in a patient with normcal "'I uptake. In rats chronically treatedl with lithiumii (5) the rate of release of thyroid 1311 was reduced 1w as much as 80% and this wN-as acconmpanied bv the gradual development of small goiters. Other parameters of iodine metabolism were not markedly affected or were stimuitilated.
Antitlhvroid agents whiclh block organification of inorganiic io(dine produce clinical relief of hyperthyroidismii only after thyroid iodine stores are depleted, and this depletion may take many weeks to occur (6. 7) . The only therapeutic agents that inhibits release of thyroid hormone directly is inorganic iodine, but problemis created by its use include interference witlh a number of diagnostic nmeasurements of thyroid function, a significant incidence of poor response or even exacerbated thyrotoxicosis (8) , and delay of 131J therapy. We therefore investigated Li' as a potential therapeutic agent in patients in whom a prompt decrease in thyroid hormone levels is required (1) . While these studies were in progress, Burrow, Burke, Himmelhoch, Spencer. and Hershman (9) reported that lithium administration slowed the loss of 13.I from the thyroid glainds of tw o thvrotoxic patients.
METHODS

Subjects
Seveni thyrotoxic patients were referred to us by Washinigton area plhysicians. ( We thank Doctors Larry Aniderson, I Patient G. F. was studied twice.
Alice Brigham, Mason Robertson, Jay Shapiro, and Aryangat Sukamara for these referrals.) With one exception (G. V. had a widened mediastinum of uncertain etiology) they were found to be free of other significant illness, and were felt to be able to tolerate the delay in beginning established antithyroid therapy that was required for the study. All patients were females with diffusely enlarged thyroids; their clinical features are summarized in Table I . Those subjects who had been treated with thiocarbamide drugs before the study had not yet had a satisfactory response. All antithyroid therapy was discontinued for at least 6 days before the onset of the study. One patient was studied twice. (10) and cholesterol were measured three times a week; BMR was measured twice a week, using a Sanborn model 10 "Metabulator"; free thyroxine (performed by BioScience Laboratories, Van Nuys, Calif. [11] ) and thyroxine binding globulin (performed by BioScience) were measured weekly. The resting pulse was taken at least once per night. In four studies, methimazole (methylmercaptoimidazole) (30 mg each 6 hr) was begun 1-5 days after 131I administration and was continued until the study was completed.
Procedures
For several days before the start of lithium administration, lactose placebos were given every 8 hr. When rapid changes in the kinetic curves had ceased, lithium carbonate was substituted for the lactose placebo without the patient's knowledge. Serum Li+ levels were then measured daily by atomic absorption spectrometry. Generally, the initial dose of lithium carbonate was 600 mg, which yielded a serum level of about 0.5 mEq/liter 8 hr later. Subsequently, 900-1500 mg per day (given in three or four doses) was required to maintain serum lithium levels of 0. Analysis of data. The kinetic data were analyzed using a general model of iodine metabolism ( Fig. 1 ) modified from Berman et al. (12) (13) (14) and the digital computer program SAAM/25, the latest of the SAAM series (15) . Beginning with a set of initial estimates for the rate constants L,,j (designated X,,j in previous papers [12, 14] ), the computer iteratively adjusted their values until a least squares fit of all the data for a particular study was obtained. Certain of the rate constants were allowed to change during the period of lithium administration and again during the period after lithium treatment. The general approach was to determine whether adjustment of a single parameter during lithium administration was sufficient for a satisfactory fit to the data, and whether failure to adjust that parameter would result in a poor fit even with all other parameters free to adjust (necessary condition). As will be seen, in some cases adjustment of a single parameter was sufficient, while in others, a second, extrathyroidal effect of Li' had to be introduced to account for the data. This second site of action would not have been detected without use of the model, and these results have suggested further studies.
The model (Fig. 1 ) provides for secretion of hormonal and nonhormonal I from several compartments (12) (13) (14) , but we did not find it necessary to introduce different lithium effects for each compartment (see legend to Fig. 1 ). The effect is therefore expressed by a single rate constant for total iodine secretion: the total fractional thyroidal iodine release rate, LT.
For any compartment i, with content Mt, the secretion of iodine into compartment j is M, -Lj, . Thus, total thyroxine secretion (RT4) is: 
RESULTS
Patients with no organification block. Figs. 2 and 3 show kinetic data from two of the four patients who received lithium without methimazole; they illustrate features common to all of these patients as well as some of the variations observed in different studies. After lithium administration there was an abrupt decrease in the rate of loss of thyroidal radioactivity and the decrease persisted throughout the period of Li' treatment. However, the thyroid release curves showed marked variation upon cessation of lithium therapy. The rate of loss increased to nearly its prelithium rate in one case, changed little in two cases (e.g., Fig. 3 ) and increased, but not to its prelithiun rate, in the fourth (Fig. 2) .
Upon initiation of Li' treatment, serum and urine 'I values fell from their pretreatment plateau values. These changes are consistent with, but do not prove, a decrease of "31I release from the gland. In three of the four patients the urinary "31I excretion fell more rapidly during the first 48-72 hr of lithium treatment than did serum 'I levels; subsequently, the two values decreased at nearly comparable rates. The urinary 'I derives from both peripheral breakdown of thyroid hormones and direct thyroidal secretion of iodide. The component arising FIGURE 2 "31I kinetics, serum T41 and serum Li+ for patient Ba. J. At time zero Na-131I was given intravenously; the shaded area is the period of lithium administration. Solid circles and triangles represent measured data while solid lines in the three upper sections of the figure are the computer-generated least squares solutions, assuming that lithium affected only iodine release. The dashed line is the computer-generated description of the behavior of the curves if lithium had n1ot been given. directly from secretion would be expected to fall rapidly after any interference with secretion and the rapid early fall of urinary 'I reflects this. Serum 'I levels, representing mainly hormone iodine, decay slowly even after an abrupt decrease in secretion. The portion of urinary iodide derived from serum "I declines in parallel with it. In three of the four studies (the exception is Br. J., Fig. 3 ) discontinuation of lithium treatment led to increased urinary "31I excretion and serum 'I levels.
The kinetic data were analyzed as described in Methods. The least squares fits are drawn in solid lines in the figures, whereas the dashed lines represent the behavior of '31I that would have occurred without Li' therapy in these patients. For Ba. J. (Fig. 2) , who was mildly thyrotoxic on the basis of nonsuppressible 'I uptake and elevated T3, the data could be fitted, with an acceptably small error (solid line, Fig. 2 (Table I ). The abrupt change in neck counts, the diminution of urinary 'I excretion, and the fall of serum total and protein-bound 'I are more impressive than in the study of Ba. J. In contrast to Ba. J. (Fig. 2) , the data could not be fitted by assuming that lithium affected a single parameter (total 'I release rate). If parameters were adjusted to fit the serum data (Fig. 3A) marked deviations betwee-n the model (solid lines) and the data occurred in both the urine and thyroid curves. When, on the other hand, they were adjusted to fit the thyroid data, a reasonable fit to the observed urine data could be obtained, but satisfactory matching of the serum kinetic curve could not be achieved (Fig. 3B) . Since the fit of the data before Li+ treatment was satisfactory, it seemed that the deviations in the serum curve resulted from the Li' therapy. The too rapidly falling serum curve suggested, furthermore, that if the serum 'I disappearance were decreased a better fit mnight be obtained. Introduction of a factor to correct for the extent of the deviation in serum "I yielded much improved fits (Fig. 3C) . Moreover, the post-Li' recovery showed an improved fit as well.
It is of considerable interest that while a Li' effect on release was anticipated from our rat studies (5) and would be consistent with the neck counts in these patients, an effect on T4 disappearance from the serum was not expected from the rat data and was not observed in one case of thyrotoxicosis.2 For these reasons T4 disappearance studies were not performed in our patients. The rigorous testing of the model, however, required this additional locus of lithium action. The effect on disappearance could be due to changes in one of the following: fecal excretion rate, thyroxine space, or degradation rate. Since the higher serum 'I is accompanied by diminished loss of radioactivity in the urine (e.g., Fig.  3A) , it seems reasonable to ascribe this second Li' effect to decreased deiodination. In our modeling, therefore, the lithium effect on T4 disappearance has been placed in the deiodination pathway (Li,14) and we have left the rate of fecal losses unaltered (L 4ee..). This is not meant to suggest that the latter parameter could not be affected; only that we did not need to introduce any change to obtain the quality of fit shown. It should be pointed out that eveni with this improved fit the model shows two areas of discrepancy with the data. Both of these occur during periods of changing Li' concentration (i.e., onset and cessationi of therapy). Although no attempt was made to develop a dose response curve for the lithium effect, changes in the rate of "3'I loss from the gland and in the rate of urinary 131I excretion could be detected in all patients writhin 24 hr after the first lithium dose. At that time the serum lithium was never more than 0.5 mEq/liter, which can thus be taken as an upper limit for the minimum effective dose. However, a full Li' effect was probably not attained at this time and, since the model assumed an instantaneous Li' effect, the early deviations may be due to this approximation.
The other two patients, A. T. and G. F.-1v who were treated with Li' alone, showed essentially similar responses in their iodine kinetics. In A. T. a relatively small effect was obtained (Table II) and changes in degradation rate were not acquired to obtain a good fit of the data to the model. The poor response may be due to the fact that Li' levels hovered around 0.6 mEq/liter. The study of G. F.-1 gave results rather similar to those of Br. J., except that during the second week of lithium therapy there was a diminution of the lithium effect associated wvith a fall in serum lithiutm from about 1.0 mEq/liter to 0.6 mEq/liter. Recovery of the kinetic parameters was variable. A. T. showed a return to normal of all "'I parameters when the serum Li' had declined to < 0.1 mEq/liter, whereas G. F.-1 showed an incomplete return to the pretreatment rate of loss of "31I from the thyroid (Table II) Serum 13"I levels were allowed to plateau before Li' treatment was begun. In G. F.-2 the methimazole period was shortened because of severe thyrotoxicity. With lithium administration, serum 131I began to decline and continued to do so, although at a decreasing rate, until the lithium was discontinued, at which time it either stabilized at about 40-50% of the prelithium values (Fig. 5) or rose slightly (Fig. 4) The return toward pretreatment rates of these kinetic paranmeters upon cessation of Li' therapy is also listed in Table II . These values are rough indications, since the mechanism to explain inconsistencies in that region of the data has not yet been worked out. Again there is a wide spectrum of response. Br. J. showed little recovery in either parameter, whereas A. T. and G. F.-2 attained values exceeding the pretreatment rates. It appeared that "3I release from the thyroid returned toward normal rates more often than did the thyroxine deiodination rate, but more data are needed before this can be stated with any assurance.
Effect on serum "I-hormone levels. The effect of lithium given with and without methimazole on the serum T4I is summarized in Table III. In the unblocked patients there was a 25-32% decrease in T41 within 4-5 days, after which there was essentially no further fall, even though the PB-1I continued to decline. When lithium was discontinued, there was a rapid (within 4 days) return of the serum T4I to pretreatment levels in three of the four patients. The exception was Br. J. (Fig. 3C ) in whom this return took about 2 wk.
Methimazole-treated patients had a more striking fall (23-59% in 4-5 days) of serum hormone levels, three of four reaching a normal serum Td 4-5 days after the start of lithium (the exception, G. V., fell to the upper limit of normal at 10-11 days, despite her failure to respond to 2 months of treatment with high doses of methimazole). In contrast to the unblocked patients, hormone levels continued to fall with continued lithium administration. In addition, the rapid postlithium recovery of serum TI levels did not occur (Figs. 4 and 5) , hormone levels rising only slightly. Serum T3 levels were measured before and after lithium administration in five patients, and appeared to fall somewhat more than the T~levels (Table III) . Because of more rapid disappearance rates the Ts levels might be expected to fall more rapidly. Studies of early T3 changes are now in progress.
Clinical changes. The clinical response to lithium correlated in general with the changes of serum T~I levels (Table III) . Thus the four patients treated with lithium alone and G. V., of the lithium-methimazole group (only two of whom, Br. J. and G. F.-1, were very symptomatic), had only small changes toward norjmal. In Br. J., who had the greatest TAI response of that group, a fall in resting pulse (100-86) and BMR (+ 31-± 19) was demonstrated. The greater fall in serum hormone levels in three of the four patients treated with both lithium and methimazole corresponded with a more impressive clinical response, when this could be evaluated. D. B., who was quite symptomatic, became wholly free of symp- Normal 0.6-1.6 ng/ml. § The values in parentheses represent the per cenit fall from prelithium levels during lithiutm therapy.
toms and also had a significant fall in pulse (74-57) and BMR (49-24). H. B. and G. F.-2 also became free of thyrotoxic symptoms, but evaluation was hindered in the former by an upper respiratory infection (pulse and BMR did not fall) and in the latter by the use of propranolol.
In no patient was a change in thyroid gland size noted during the study. Cholesterol levels did not change remarkably in any of the patients. Measurement of free T4 confirmed changes noted in total thyroxine-iodine values. Thyroxine-binding globulin, antithyroglobulin antibodies, and other laboratory determinations did not change significantly during lithium treatment.
The possibility that lithium produced a calming effect on hyperthyroid patients apart from its antithyroid action was considered, but we were unable to detect such a phenomenon. As part of our attempt to evaluate mental changes the study was double blind for both the patient and the psychiatric staff. Although mild depression was observed in several patients, it was associated with the mild anorexia and nausea that occurred at least transiently in most cases, and could not be interpreted as an independent effect. No evidence of lithium toxicity other than gastrointestinal disturbances was observed; in no case were these symptoms severe enough to require discontinuation of the drug, although in G. F.-1 the dose was reduced because of nausea and vomiting. DISCUSSION The present data show that low serum concentrations of lithium ion (0.5-1.0 mEq/liter) lead rapidly to a 30-85% decrease in the secretion of both iodide and hormonal iodine from the toxic human thyroid gland, reflected simultaneously in an increased thyroid 13"I half-life, decreased urinary "3'I excretion, and declining serum "31I and serum thyroxine iodine. The decreased secretion rate follows rapidly the attainment of serum lithium levels of 0.5 mEq/liter. The effect of lithium was unaltered when iodination was blocked with methimazole. Our data were compatible with a model that assumed coordinate inhibition by lithium of hormonal and nonhormonal iodine release. Such inhibition suggests decreased thyroglobulin hydrolysis, which would reduce secretion of all thyroglobulin components equally. Recent studies in laboratory animals (16, 17) showing that low doses of lithium given in vivo inhibit in vitro colloid droplet formation in response to TSH or dibutyryl cyclic-AMP, strongly support this interpretation.
An unexpected finding, and one that differed from our rat data (5) and from studies in one thyrotoxic 2 and several euthyroid 3 T4 disappearance rates following Li' treatment that are entirely in agreement with those presented in Table II. The decrease in hormone degradation that accompanies the decreased hormone secretion induced by Li' tends to diminish the fall in serum hormone levels. In some patients (e.g., G. F.-1, Br. J.) the changes in the two parameters would appear to cancel one another. The fact that the serum T4 falls in these patients is consistent with our assumption that fecal T4 losses are unaffected by lithium, with only losses by deiodination pathways being inhibited. Studies to measure directly the effects of lithium on fecal T4 losses are currently in progress.
The model does not at present include a pathway for conversion of T4-'3'I to T3-'I. With the extent of T4 to T3 conversion a matter of controversy at present, inclusion of the pathway would have necessitated selection of wholly arbitrary rate constants and would not have affected our findings of decreased thyroid iodine release and decreased T4 deiodination. We plan direct exploration of the T4 to T3 subsystem in the future, especially with regard to the possibility that lithium might inhibit this conversion.
The present model does not require a lithium effect on iodide uptake. This is in agreement with some studies (9) but contrasts with others in which uptake was decreased (19, 20) or increased (3) (4) (5) . Increased iodide uptake might accompany lithium-induced goiter caused by low circulating T4 and T3 with elevated TSH (3, 5, 9, 21, 22) . However, none of the present group of thyrotoxic patients became hypothyroid.
The rigorous testing of the model raised several points that require further investigation and analysis. In addition to the effect on hormone disappearance there also seems to be a delayed effect in the action of Li'. This means that instead of plasma Li' some other Li' compartment is probably the important variable to consider. In neglecting these factors the model solution still contains some systematic deviations. It may even be necessary to introduce some time-dependent effects. Until this is investigated in detail and resolved, conclusions about other sites of action of lithium cannot be made with confidence. Hence, the above statements regarding fecal loss and iodide uptake contain an element of uncertainty.
A decreased iodine release rate accompanied by unchanged iodine uptake implies that in unblocked glands, iodine might be expected to accumulate, and such an accumulation has been found in lithium-treated rats (5) .
The thyroid iodine pools of the lithium-treated patients who did not receive methimazole have been calculated to have increased. This would tend to minimize the fall in serum T4 in these patients, as was observed (Figs. 2 and  3 and Table III) , and may partly explain the rapid rise of hormone levels when lithium was stopped.
Patients treated with methimazole could not accumulate iodine. This may explain the continued fall of serum and the absence of a substantial postlithium rise in T4I levels.
Except for lithium, iodide is the only agent in clinical use that affects iodine release from the thyroid gland. Iodide decreases 'I release from previously labeled thyroid glands in Graves' disease in the presence (23) (24) (25) (26) or absence (23, 27, 28) of methimazole blockade of uptake. It also inhibits TSH-stimulated release of iodine in experimental animals (29) and normal patients (25, 26) . Wartofsky, Ransil, and Ingbar have recently studied the inhibition of thyroxine release by iodine (23) . They found in eight patients that the thyroxine release rate was inhibited an average of 72.8% (range 61.2-91.5%), a somewhat greater inhibition than we have demonstrated for lithium. In a striking parallel to the Li' effect, serum thyroxine levels fell only 26-48% and tended to level off in 3.5-6.5 days, whether or not methimazole was used with the iodine.
A further similarity between iodine and lithium is the difficulty in controlling thyrotoxicosis for long periods with either agent. In a recent study, Harden, Koutras, Alexander, and Wayne (30) found that patients with good clinical and T4 responses to iodide treatment at the end of 2 wk had relapsed by the end of 4 wk despite continued therapy, their T values returning to pretreatment levels. Since iodine accumulates in thyrotoxic glands treated with Lugol's solution (31), we suggest that in patients treated either with iodide (23, 30) or lithium alone, increased glandular hormone content permits total hormone release to rise despite a decreased fractional rate of secretion. This eventually leads to escape from control. Hence the chief use for either agent alone is for short-term, rapid suppression of thyroid secretion. The addition of methimazole or another thiocarbamide drug is necessary to prevent escape from such suppression with prolonged use. Given the uncertainty regarding complete prevention of an iodine leak through methimazole block and the role of iodine as thyroid hormone substrate, lithium appears to be the preferred agent when a rapid inhibition of hormone secretion is required. These considerations must be weighed against the possible toxic effects of lithium and the possibility that the inhibition of T4 disappearance by lithium may impair its effectiveness in some instances.
